Clark Capital Management Group Inc. Has $66.81 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Clark Capital Management Group Inc. grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 3.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 189,341 shares of the biotechnology company’s stock after purchasing an additional 7,053 shares during the quarter. Clark Capital Management Group Inc. owned approximately 0.42% of United Therapeutics worth $66,807,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. bought a new position in United Therapeutics during the fourth quarter worth $25,000. Dunhill Financial LLC lifted its position in shares of United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 50 shares during the period. Millstone Evans Group LLC bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $67,000. MassMutual Private Wealth & Trust FSB boosted its stake in United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 58 shares during the last quarter. Finally, Natixis purchased a new stake in shares of United Therapeutics in the fourth quarter valued at about $85,000. Institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on UTHR shares. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $314.00 target price (down from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Morgan Stanley lifted their price target on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an “equal weight” rating in a report on Thursday, May 1st. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 2nd. UBS Group increased their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, Bank of America raised United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 target price for the company in a report on Monday, April 21st. Four equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $392.00.

Insider Activity

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $371.05, for a total value of $3,710,500.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $956,195.85. This represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total value of $3,367,980.00. Following the completion of the transaction, the executive vice president now directly owns 36,781 shares of the company’s stock, valued at approximately $11,261,606.58. This represents a 23.02 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 75,500 shares of company stock valued at $24,245,880. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Stock Performance

Shares of UTHR opened at $306.96 on Thursday. United Therapeutics Co. has a fifty-two week low of $260.41 and a fifty-two week high of $417.82. The firm has a 50 day moving average price of $300.72 and a 200-day moving average price of $343.05. The firm has a market cap of $13.85 billion, a price-to-earnings ratio of 13.48, a PEG ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company’s quarterly revenue was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.17 earnings per share. As a group, equities research analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.